Since 1985, Domain has raised eight funds and has been involved in the formation of more than 260 portfolio companies. Our companies have created numerous U.S. approved products that have advanced human health. We have developed innovative investment models, such as specialty pharma and Japanese in-licensing, which have proven successful and have been widely emulated in the life sciences industry. Domain has raised more than $2.7 billion in capital. We are engaged in new collaborations, including Domain’s investments in Russia and China with Rusnano and Beijing Elite, respectively.


To move along the timeline, drag the rectangle at the bottom horizontally. Click on an event for more information.